Englumafusp Alfa and Glofitamab Show Promise in Relapsed or Refractory B Cell Lymphoma

A phase 1 trial published July 16, 2026, in Nature Medicine found that combining the co-stimulatory molecule englumafusp alfa with the bispecific antibody glofitamab produced encouraging preliminary clinical responses and acceptable safety signals in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

The study focused on patients whose cancer had returned or failed to respond to standard treatments. According to the Nature Medicine report, the combination therapy targeted B-cell malignancies by utilizing both a bispecific antibody and a CD19–4-1BBL molecule to enhance the immune response against cancer cells.

Researchers noted that mechanistic data from the trial supported the rational choice of this specific therapy combination. The goal was to determine if the addition of englumafusp alfa could improve the efficacy of glofitamab while maintaining a manageable safety profile.

Mechanism of Englumafusp Alfa and Glofitamab

The trial investigated a dual-action approach to treating aggressive B-cell non-Hodgkin lymphoma. Glofitamab is a bispecific antibody designed to bring T cells into direct contact with B cells, marking them for destruction by the immune system.

Englumafusp alfa acts as a co-stimulatory molecule. According to the study published in Nature Medicine, it targets CD19 and provides a 4-1BBL signal. This signal is intended to activate and sustain the T cells that the bispecific antibody recruits, potentially preventing the immune cells from becoming exhausted during the attack on the tumor.

By combining these two agents, the researchers sought to create a more potent immune response than what is typically achieved with a single-agent bispecific antibody therapy.

Phase 1 Trial Safety and Clinical Responses

The primary objective of the phase 1 trial was to assess safety and determine the appropriate dosing. The results indicated that the safety signals were acceptable, meaning the side effects observed were within expected parameters for this type of immunotherapy.

In terms of efficacy, the researchers reported encouraging preliminary clinical responses. While phase 1 trials are not designed to prove a drug’s full effectiveness, the initial data suggested the combination was active in reducing tumor burden in patients with relapsed or refractory disease.

The study authors stated that the mechanistic data aligned with the clinical observations, suggesting that the biological interaction between the CD19–4-1BBL molecule and the bispecific antibody worked as hypothesized in a human setting.

Context for Aggressive B-Cell Non-Hodgkin Lymphoma

Aggressive B-cell non-Hodgkin lymphoma represents a group of fast-growing cancers of the lymphatic system. Patients who experience relapses or whose disease is refractory to initial chemotherapy often have limited treatment options, making the development of new immunotherapy combinations a priority in oncology.

Bispecific antibodies, such as glofitamab, have emerged as a key tool in treating these cancers. However, the immune system sometimes fails to maintain a strong enough attack to fully eradicate the cancer. The addition of co-stimulatory molecules like englumafusp alfa is a strategy designed to overcome this immune resistance.

This research falls under the broader categories of molecular medicine and cancer research, specifically focusing on how to manipulate the immune system’s signaling pathways to improve patient outcomes in hematologic malignancies.